| Literature DB >> 35886175 |
Mika Venojärvi1, Jaana Lindström2, Sirkka Aunola3, Pirjo Nuutila4, Mustafa Atalay5.
Abstract
(1) Objective: The aim of this study was to clarify the role of adipokines in the regulation of glucose metabolism in middle-aged obese subjects with impaired glucose tolerance in response to a long-term exercise and dietary intervention. (2)Entities:
Keywords: adipokines; aerobic capacity; glycemic control; impaired glucose tolerance; physical activity
Mesh:
Substances:
Year: 2022 PMID: 35886175 PMCID: PMC9320448 DOI: 10.3390/ijerph19148327
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Figure 1Weight-loss during the 2-year intervention in the subgroups of responders and non-responders in the IGT subjects.
Baseline characteristics of the subjects with impaired glucose tolerance (IGT) subdivided into the non-responders and responders.
| Characteristics | Non-Responders | Responders | |
|---|---|---|---|
| 9 (2/6) | 13 (4/9) | n.s | |
| Age (years) | 57.1 ± 2.3 | 55.1 ± 2.0 | n.s |
| Height (cm) | 174.2 ± 1.5 | 172.6 ± 2.2 | n.s |
| Weight (kg) | 89.7 ± 1.8 | 89.7 ± 2.9 | n.s |
| BMI | 29.5 ± 0.6 | 30.1 ± 0.7 | n.s |
| WHR | 0.96 ± 0.02 | 0.96 ± 0.02 | n.s |
|
| |||
| VO2max(L/min) | 2.37 ± 0.22 | 2.26 ± 0.18 | n.s |
| VO2peak (mL/kg−1/min) | 26.7 ± 2.7 | 26.2 ± 1.9 | n.s |
|
| |||
| MHC I | 38.0 ± 3.0 | 37.9 ± 3.3 | n.s |
| MHC IIa | 41.6 ± 2.7 | 43.4 ± 3.2 | n.s |
| MHC IIx | 21.0 ± 2.7 | 18.7 ± 2.8 | n.s |
|
| |||
| Energy intake, kcal/day | 1823 ± 143 | 1925 ± 169 | n.s |
| Alcohol, E% | 2.6 ± 1.3 | 4.5 ± 1.2 | n.s |
| Carbohydrates, E% | 44.7 ± 2.0 | 42.5 ± 1.8 | n.s |
| Fat, E% | 35.6 ± 1.6 | 35.1 ± 1.1 | n.s |
| Protein, E% | 17.1 ± 1.2 | 17.9 ± 0.7 | n.s |
| Dietary fiber, g/day | 22.3 ± 2.1 | 19.7 ± 1.9 | n.s |
Data are presented as means ± SE. Kruskal–Wallis test between groups. n.s non-significant, BMI: body mass index, WHR: waist-hip-ratio, MHC: myosin heavy chain, VO2max: maximal oxygen uptake, VO2peak: peak oxygen uptake, E% = percent of energy intake.
List of primers and probes used in the RT-PCR assay.
| GAPDH | |
| Probe | 5′-ACCAGGCGCCCAATACGACCAA-3′ |
| Forward primer: | 5′-GTTCGACAGTCAGCCGCATC-3′ |
| Reverse primer: | 5′-GGAATTTGCCATGGGTGGA-3′ |
| GLUT-4 | |
| Probe: | 5′-CTC-AGC-CAG-CAC-TCC-AGA-AAC-ATC-GG-3′ |
| Forward primer: | 5′-AAG-AGT-CTG-AAG-CGC-CTG-ACA-3′ |
| Reverse primer: | 5′-CAG-CTT-CCG-CTT-CTC-ATC-CT-3′ |
| INF-γ | |
| Probe: | 5′-TGCTGGCGACAGTTCAGCCATCAC-3′ |
| Forward primer: | 5′-CTCGAAACAGCATCTGACTCCTT-3′ |
| Reverse primer: | 5′-TGTCCAACGCAAAGCAATACA-3′ |
| IRS-1 | |
| Probe: | 5′-AAACCCATTCTCTCATGACACGGTGGTG-3′ |
| Forward primer: | 5′-TCTCCACCCAACGTGAACAGT-3′ |
| Reverse primer: | 5′-CTGCATAAACTTCATCTTCAACCTTAAG-3′ |
| TNF-α | |
| Probe: | 5′-CATCTTCTCGAACCCCGAGTGACAAGC-3′ |
| Forward primer: | 5′-TGGCCCAGGCAGTCAGA-3′ |
| Reverse primer: | 5′-GGTTTGCTACAACATGGGCTACA-3′ |
GAPDH: glyceraldehyde-3-phosphate dehydrogenase, INF-γ: interferon-γ, GLUT-4: glucose transporter protein-4, IRS-1: insulin receptor substrate-1, TNF-α: tumor necrosis factor.
Exercise frequency and changes in muscle fiber composition occurring during 2-year intervention in the IGT subjects.
| Non-Responders | Responders | |
|---|---|---|
| Exercise frequency (hours/week) | ||
| Moderate and heavy aerobic training | 1.2 ± 0.3 | 1.3 ± 0.3 |
| Strength and power training | 2.4 ± 0.6 | 1.3 ± 0.2 |
| Walking and lighter aerobic training | 1.7 ± 0.6 | 2.3 ± 0.4 |
| Total amount of training | 5.4 ± 0.8 | 4.9 ± 0.8 |
| Muscle fiber composition% | ||
| ΔMHC I | −1.5 ± 1.4 # | 3.8 ± 1.7 * |
| ΔMHC IIa | 1.3 ± 2.0 | 1.0 ± 2.6 |
| ΔMHC IIx | 0.2 ± 2.0 | −4.9 ± 2.8 |
Data are presented as means ± SE; * p < 0.05 within groups using paired Student t-test; # p< 0.05 between groups using Kruskal–Wallis test.
Aerobic performance capacity and dietary intake at baseline and after the 2-year in IGT subjects.
| Non-Responders | Responders | |||
|---|---|---|---|---|
| Baseline | 2-Year | Baseline | 2-Year | |
| Aerobic performance capacity | ||||
| CS (μmol/g wet weight muscle tissue) | 22.9 ± 3.4 | 25.6 ± 3.2 | 22.6 ± 2.0 | 31 ± 3.2 ** |
| VO2max (L/min) | 2.37 ± 0.22 | 2.52 ± 0.22 * | 2.26 ± 0.18 | 2.37 ± 0.17 ** |
| VO2peak (mL//kg/min) | 26.7 ± 2.7 | 28.1 ± 2.5 | 26.2 ± 1.9 | 28.8 ± 1.9 *** |
| Dietary intake | ||||
| Energy intake, kcal/day | 1823 ± 143 | 1916 ± 169 | 1925 ± 169 | 1886 ± 136 |
| Alcohol, E% | 2.6 ± 1.3 | 2.1 ± 1.0 | 4.5 ± 1.2 | 5.4 ± 2.1 |
| Carbohydrates, E% | 44.7 ± 2.0 | 47.0 ± 2.6 | 42.5 ± 1.8 | 46.1 ± 2.1 |
| Fat, E% | 35.6 ± 1.6 | 33.2 ± 1.3 | 35.1 ± 1.1 | 30.6 ± 1.1 * |
| Protein, E% | 17.1 ± 1.2 | 17.6 ± 1.3 | 17.9 ± 0.7 | 17.9 ± 0.7 |
| Dietary fiber, g/day | 22.3 ± 2.1 | 23.2 ± 2.8 | 19.7 ± 1.9 | 22.7 ± 1.4 * |
Data are presented as means ± SE; * p < 0.05, ** p < 0.01, *** p < 0.001 within groups using paired Student t-test. CS: citrate synthase, VO2max: maximal oxygen uptake, E% = percent of energy intake.
Effects of a 2-year exercise–diet intervention on parameters reflecting glucose lipid metabolism in the IGT subjects.
| Non-Responders | Responders | |||||
|---|---|---|---|---|---|---|
| Baseline | 2-Year | Changes | Baseline | 2-Year | Changes | |
| Fs-Ins (μU/mL) | 16.7 ± 2.7 | 17.0 ± 3.0 | 0.3 ± 2.7 | 16.4 ± 2.1 | 11.2 ± 1.3 ** | −5.2 ± 1.3 |
| 2 h Ins (μU/mL) | 96 ± 23 | 81 ± 22 | −15 ± 19 # | 97 ± 33 | 45 ± 90 | −55 ± 30 |
| HbA1c (%) | 5.6 ± 0.1 | 5.4 ± 0.1 | −0.2 ± 0.1 | 5.8 ± 0.1 | 5.3 ± 0.1 *** | −0.5 ± 0.1 |
| Fs-Gluc (mmol/L) | 6.0 ± 0.1 | 6.1 ± 0.2 | 0.1 ± 0.1 ## | 6.1 ± 0.1 | 5.6 ± 0.1 *** | −0.5 ± 0.1 |
| 2 h Gluc (mmol/L) | 8.1 ± 0.3 | 7.0 ± 0.8 | −1.1 ± 0.9 | 7.4 ± 0.4 | 6.0 ± 0.4 * | −1.4 ± 0.5 |
| Bennett I | 0.51 ± 0.02 | 0.52 ± 0.02 | 0.01 ± 0.01 ## | 0.51 ± 0.02 | 0.57 ± 0.02 ** | 0.06 ± 0.01 |
| HOMA-IR | 4.5 ± 0.8 | 4.6 ± 0.9 | 0.1 ± 0.8 # | 4.5 ± 0.6 | 2.8 ± 0.3 ** | −1.7 ± 0.4 |
| McAuley I | 5.8 ± 0.3 | 5.7 ± 0.4 | −0.2 ± 0.2 ## | 5.6 ± 0.4 | 6.5 ± 0.3 ** | 1.0 ± 0.2 |
| Cholesterol (mmol/L) | 5.3 ± 0.3 | 4.9 ± 0.2 * | −0.4 ± 0.2 # | 5.6 ± 0.2 | 5.5 ± 0.3 | −0.1 ± 0.1 |
| LDL (mmol/L) | 3.5 ± 0.3 | 3.0 ± 0.2 ** | −0.5 ± 0.12 # | 3.7 ± 0.3 | 3.5 ± 0.3 | −0.1 ± 0.12 |
| HDL (mmol/L) | 1.10 ± 0.10 | 1.14 ± 0.10 | 0.05 ± 0.03 | 1.14 ± 0.09 | 1.26 ± 0.09 | 0.11 ± 0.05 |
| Triglyceride (mmol/L) | 1.54 ± 0.15 | 1.76 ± 0.21 | 0.22 ± 0.06 *,## | 1.96 ± 0.24 | 1.55 ± 0.18 * | −0.42 ± 0.13 |
| FFA (mmol/L) | 0.68 ± 0.07 | 0.47 ± 0.07 | −0.21 ± 0.11 | 0.69 ± 0.07 | 0.47 ± 0.04 ** | −0.22 ± 0.06 |
| γ-GT (IU/L) | 36.3 ± 3.2 | 31.4 ± 5.0 | −4.9 ± 3.1 | 40.9 ± 5.1 | 31.5 ± 4.5 ** | −9.4 ± 2.9 |
Data are presented as means ± SE; * p < 0.05, ** p < 0.01, *** p < 0.001 within groups using paired Student t-test; # p < 0.05, ## p < 0.01 between groups using Kruskal–Wallis test. Fs-Ins: fasting insulin, HbA1c: Haemoglobin A1c, I: index, HOMA-IR: Homeostasis Model Assessment, insulin resistance, Fs-Gluc: fasting glucose concentration, 2 h Gluc: glucose concentration at 2 h of oral glucose tolerance test, LDL: low-density lipoprotein, HDL: high-density lipoprotein, FFA: free fatty acids, γ-GT: γ-glutamyltransferase.
Effects of a 2-year exercise–diet intervention on the parameters depicting adipokines and cytokines in IGT subjects.
| Non-Responders | Responders | |||||
|---|---|---|---|---|---|---|
| Baseline | 2-Year | Changes | Baseline | 2-Year | Changes | |
| Adiponectin (μg/mL) | 6.8 ± 1.5 | −0.3 ± 0.5 | 7.6 ± 1.3 | 8.5 ± 1.2 * | 1.0 ± 0.5 | 7.1 ± 1.2 |
| IL-6 (pg/mL) | 3.5 ± 1.9 | 3.7 ± 2.1 | 0.2 ± 0.3 | 2.9 ± 2.0 | 2.2 ± 1.4 | −0.7 ± 0.6 |
| Leptin (pg/mL) | 11.7 ± 3.1 | 13.4 ± 3.8 | 1.7 ± 1.0 | 14.2 ± 3.6 | 10.4 ± 3.2 ** | −3.8 ± 1.0 ## |
| MCP-1 (pg/mL) | 348 ± 52 | 307 ± 43 | −41 ± 24 | 279 ± 35 | 291 ± 43 | 11 ± 29 |
| TNF-α (pg/mL) | 5.4 ± 0.9 | 5.8 ± 1.2 | 0.4 ± 0.5 | 4.5 ± 0.7 | 4.6 ± 0.6 | 0.03 ± 0.5 |
Data are presented as means ± SE; * p < 0.05, ** p < 0.01 within groups using paired Student t -test; ## p < 0.01 between groups using Kruskal–Wallis test. IL-6: interleukin-6, MCP-1: monocyte chemoattractant protein-1, TNF-α: tumor necrosis factor.
Figure 2Relative changes in the gene expressions of INF-γ, IRS-1, GLUT-4 and TNF-α after the 2-year exercise–diet intervention in the skeletal muscles of the IGT subjects.
Figure 3Protein expressions of AMPK- α1 (A) and AMPK-α2 (B) in skeletal muscle of IGT subjects. (C) Representative Western blots, using anti-AMKP-α1 and AMPK-α2 and beta-actin antibodies from skeletal muscle biopsies of non-responders and responders at baseline (0) and after the 2-year intervention.
Correlation coefficients between weight loss and maximal oxygen uptake (VO2peak) and laboratory parameters.
| Non-Responders | Responders | |||
|---|---|---|---|---|
| Weight Loss | VO2peak | Weight Loss | VO2peak | |
| Change: adiponectin | −0.477 | 0.258 | −0.514 | −0.178 |
| Change: citrate synthase | 0.152 | −0.330 | 0.079 | 0.040 * |
| Change: leptin | 0.171 | −0.347 | 0.662 * | 0.141 |
| Change: Bennett | −0.129 | 0.540 | −0.506 | 0.831 ** |
| Change: HOMA-IR | 0.327 | −0.632 | 0.220 | −0.520 |
| Change: McAuley | 0.063 | 0.457 | −0.344 | 0.890 ** |
Pearson correlation test, * p < 0.05, ** p < 0.01.